SML1893
RO5256390
≥98% (HPLC), TAAR1 agonist, powder
别名:
(S)-4-((S)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C13H18N2O
化学文摘社编号:
分子量:
218.29
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
产品名称
RO5256390, ≥98% (HPLC)
InChI
1S/C13H18N2O/c1-2-10(11-6-4-3-5-7-11)8-12-9-16-13(14)15-12/h3-7,10,12H,2,8-9H2,1H3,(H2,14,15)/t10-,12-/m0/s1
SMILES string
CC[C@@H](C[C@H]1COC(N)=N1)C2=CC=CC=C2
InChI key
IXDKFUBXESWHSL-JQWIXIFHSA-N
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D 14 to 19°, c = 1 in methanol
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
RO5256390 is an agonist of Trace amine-associated receptor 1 (TAAR1), a GPCR primarily found in the brain, expressed in areas where the major monoamine amine transmitters (DA and NE) are also present. RO5256390 is a selective TAAR1 agonist shown to be a negative regulator of dopamine transmission. It has antipsychotic activity in models of schizophrenia, reduces cocaine′s reinforcng effects, and blocks binge-eating disorder.
TAAR1 agonist
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Vincent M Lam et al.
European journal of pharmacology, 763(Pt B), 136-142 (2015-06-21)
Trace-amines (TAs) are endogenous amines that are implicated in several physiological processes including modulation of aminergic neurotransmission. These compounds exert their effect by activating a class of G protein-coupled receptors termed Trace-Amine Associated Receptors (TAARs), where TAAR1 is the only
Antonio Ferragud et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 42(7), 1458-1470 (2016-11-03)
Compulsive, binge eating of highly palatable food constitutes a core feature of some forms of obesity and eating disorders, as well as of the recently proposed disorder of food addiction. Trace amine-associated receptor 1 (TAAR1) is a highly conserved G-protein-coupled
F G Revel et al.
Molecular psychiatry, 18(5), 543-556 (2012-05-30)
Schizophrenia is a chronic, severe and highly complex mental illness. Current treatments manage the positive symptoms, yet have minimal effects on the negative and cognitive symptoms, two prominent features of the disease with critical impact on the long-term morbidity. In
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持